Madrigal logo.jpg
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
February 25, 2021 06:50 ET | Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We...
Casana_Heart Seat
Casana Raises $14 Million in Series A Funding Led by General Catalyst for In-home Heart Health Monitoring Device
February 03, 2021 08:12 ET | Casana Care, Inc.
ROCHESTER, N.Y., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Casana, previously known as Heart Health Intelligence, Inc., a healthcare technology firm that is re-inventing in-home health monitoring, today...
Reports and Data.jpeg-01
Biomarkers Market Size Worth $115.45 Billion By 2027 | CAGR of 13.6%: Reports And Data
December 11, 2020 11:21 ET | Reports and Data
New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- The market growth is driven by technological advancements in post-genomic technologies and extensive applications of diagnostic biomarkers in precision...
22157.jpg
Global Atrial Fibrillation Treatment Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast
December 10, 2020 04:13 ET | Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
Madrigal logo.jpg
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
November 13, 2020 06:50 ET | Madrigal Pharmaceuticals, Inc.
Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday,...
Madrigal logo.jpg
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
November 05, 2020 06:50 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in...
NOVARTIS logo.jpg
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
October 16, 2020 07:30 ET | Novartis International AG
If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1Cardiovascular disease (CVD) claims 3.9...
Non-invasive Tests
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 Trial
October 01, 2020 08:00 ET | Madrigal Pharmaceuticals, Inc.
High accuracy in predicting advanced NASH fibrosis (F2-F3) in Phase 3 MAESTRO-NASH study using clinical characteristics and simple, readily available non-invasive imaging and biomarkersData from...
Study: Reducing Lead
Study: Reducing Lead Exposure Has Massive Benefit for Adult Population
September 23, 2020 10:11 ET | Abt Associates
Rockville, Md., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Rockville, Md.  –  An Abt Associates-led study finds that reduction in lead exposure over the past 15 years has decreased the number of...
Madrigal logo.jpg
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
September 03, 2020 06:50 ET | Madrigal Pharmaceuticals, Inc.
--Completion of enrollment in MAESTRO-NAFLD-1 will enable reporting of topline 52-week data by the end of next year as planned.--Madrigal intends to present selected data from ongoing open label arm...